Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
ATP signaling in brain: release, excitotoxicity and potential therapeutic targets
Retatrutide GLP-3 Vial All Retatrutide GLP-3 research Retatrutide (development code LY3437943) is a synthetic, once-weekly triple agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors that has been the subject of peer-reviewed phase 1 and phase 2 randomized controlled trials published in The New England Journal of Medicine, The Lancet, and Nature Medicine, including investigations of body weight, glycemic control, and hepatic steatosis in adult human participants
He is on a low dose
doi:10.1042/BST20051375
US$ 25.91
US$ 27.82
US$ 29.31
![Mechanism of action of GLP-1 [25]](https://www.researchgate.net/publication/256289222/figure/fig1/AS:614177232142337@1523442671231/Mechanism-of-action-of-GLP-1-25.png)
US$ 22.61
US$ 29.19
